XNAS · Healthcare · Biotechnology
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 0.07 | 0.02 | -71.43% | $268.1M | ❌ Miss | +0.43% | +3.26% | — |
| 2026-02-25 | Q4 2025 | 0.13 | 0.14 | +7.69% | $284.0M | ✅ Beat | +1.24% | -6.33% | -16.90% |
| 2025-11-05 |
| Q3 2025 |
| 0.14 |
| 0.26 |
| +85.71% |
| $278.6M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 0.14 | 0.16 | +14.29% | $264.6M | ✅ Beat | +0.21% | +5.59% | +6.13% |
| 2025-02-26 | Q4 2024 | 0.23 | 0.08 | -65.22% | $259.6M | ❌ Miss | +1.79% | -4.84% | -10.16% |
| 2024-11-06 | Q3 2024 | 0.14 | 0.20 | +42.86% | $250.4M | ✅ Beat | +8.93% | +11.40% | +9.44% |
| 2024-08-06 | Q2 2024 | 0.19 | 0.20 | +5.26% | $242.0M | ✅ Beat | -19.52% | -16.55% | -13.95% |
| 2024-05-08 | Q1 2024 | 0.05 | 0.10 | +100.00% | $205.8M | ✅ Beat | -11.21% | -11.73% | -13.08% |
Showing last 8 quarters.